Inflammatory arthritis in systemic sclerosis: What to do?

Area of Science:

• Rheumatology
• Immunology
• Systemic Autoimmune Diseases

Background:

• Musculoskeletal conditions like arthritis and tendinopathy are prevalent in systemic sclerosis, significantly impacting patient disability and quality of life.
• Despite the clinical importance, robust evidence from randomized controlled trials specifically for systemic sclerosis arthritis treatment is lacking.
• Validated arthritis-specific outcome measures for systemic sclerosis are currently insufficient for rigorous clinical trials.

Purpose of the Study:

• To review the current literature on the assessment and treatment of arthritis in systemic sclerosis.
• To address current management considerations for rheumatologists managing these musculoskeletal complaints.
• To highlight the need for further research and validated outcome measures.

Main Methods:

• Literature review of existing studies on systemic sclerosis arthritis.
• Analysis of consensus statements based on treatments for related autoimmune conditions.
• Evaluation of the potential role of newer biologic agents.

Main Results:

• Limited evidence exists for the direct treatment of systemic sclerosis-related inflammatory arthritis.
• Consensus recommendations support the use of methotrexate and hydroxychloroquine, drawing parallels with rheumatoid arthritis and lupus.
• Emerging biologic therapies used in other autoimmune diseases may offer future treatment avenues.

Conclusions:

• Management of systemic sclerosis arthritis requires addressing significant limitations in evidence and validated outcome measures.
• Current treatment strategies are largely based on consensus and extrapolation from related diseases.
• Further research, including well-designed clinical trials and development of specific outcome measures, is crucial for advancing patient care.